CTD Holdings Finalizes Cooperative Agreement for Alzheimer’s Disease Research Program

ALACHUA, FL–(Marketwired – April 19, 2018) – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has finalized a cooperative research agreement with Kerwin Research Center, LLC to explore the use of cyclodextrins in the treatment of Alzheimer’s disease. The principal investigator on the project is Diana Kerwin, MD, President of Kerwin Research Center and a recognized expert in Alzheimer’s disease and memory disorders who was previously part of the Northwestern University, National Institute on Aging-funded, Cognitive Neurology and Alzheimer’s Disease Center, where she oversaw clinical trials and clinical research.

“Since 2009, CTD has provided our proprietary hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™, on a compassionate basis to patients suffering from Niemann-Pick Disease Type C (NPC), a disease that causes cholesterol accumulation in every cell in the body, and today we support two clinical trials using Trappsol® Cyclo™ for that same indication,” said N. Scott Fine, Company Chairman and CEO. “With this cooperative research program, we are proud to continue to innovate by exploring the use of Trappsol® Cyclo™ in the treatment of Alzheimer’s disease.”

Cholesterol has been linked to the formation of amyloid beta plaques, one of the hallmarks of Alzheimer’s disease. Hydroxypropyl beta cyclodextrins have been shown to clear cholesterol from cells in animal models, to stabilize cholesterol metabolism, and to reduce the formation of amyloid beta plaques. Early safety data from CTD’s two clinical trials using Trappsol® Cyclo™ intravenously for NPC (NCT02939547 and NCT02912793) showed a favorable benefit:safety profile in NPC patients, per the Company’s recent announcement.

“I am excited for the opportunity to work with CTD on this potential new therapeutic approach in Alzheimer’s disease. The effects of cyclodextrin in Niemann-Pick Disease Type C and pre-clinical studies suggest a potential effect in Alzheimer’s disease,” said Dr. Kerwin. “Alzheimer’s disease affects millions and currently has no cure or disease modifying therapy. We are dedicated to furthering the understanding of Alzheimer’s and other dementias and contributing to the development of new treatment areas.”

About CTD Holdings:
CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease, on a compassionate use basis as well as in formal clinical trials (two clinical trials for this indication are currently open Clinical Trials.gov NCT02939547 and NCT02912793). Additional indications for the active ingredient in Trappsol® Cyclo™, are in development. For additional information, visit the company’s website: www.ctd-holdings.com

Safe Harbor Statement:
This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Investor/Media Contact:
Sitrick and Company

Wendy Tanaka
(415) 369-8447
[email protected]

Thomas Mulligan
(212) 573-6100, Ext. 395
[email protected]